Physician profile
Khaled Issa
NPI 1801818646
$5,450.35
in general payments reported to CMS, 2019-2025
22 companies · $1,433 in 2025
The $1,433 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,291 · 2021: $150 · 2022: $594 · 2023: $771 · 2024: $1,211 · 2025: $1,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,402 · Education: $13.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,401.83 |
| Education | $13.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,451.48 | 2020-2025 | Spyglass |
| Abbvie INC. | $1,214.07 | 2022-2025 | |
| Janssen Biotech, INC. | $393.64 | 2022-2025 | Tremfya, Stelara |
| E.R. Squibb & Sons, L.L.C. | $361.35 | 2023-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $361.33 | 2020-2022 | |
| Madrigal Pharmaceuticals | $329.47 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $222.31 | 2020-2025 | Livdelzi |
| Genzyme Corporation | $215.74 | 2023-2025 | |
| Pfizer INC. | $200.49 | 2024-2025 | |
| Lilly USA, LLC | $165.33 | 2023-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $123.12 | 2022 | |
| Celgene Corporation | $85.31 | 2023-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $79.51 | 2024-2025 | Entyvio |
| Qol Medical, LLC | $66.94 | 2023-2025 | Sucraid, Sucraid |
| Ferring Pharmaceuticals INC. | $43.27 | 2021-2023 | Rebyota |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $33.66 | 2024 | Iqirvo, Bylvay |
| Organon LLC | $25.04 | 2023 | Hadlima, Renflexis |
| Regeneron Healthcare Solutions, INC. | $17.67 | 2024 | Dupixent |
| Phathom Pharmaceuticals, INC. | $17.47 | 2024 | Voquezna |
| Novo Nordisk INC | $15.62 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.34 | 2024 | Cyltezo |
| Celltrion USA INC. | $13.19 | 2024 | Zymfentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khaled Issa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.